The article focuses on the integration process of clinical stem cell research in China in the international arena of high-profile science. This development is analyzed against the background of a well-established landscape of informal and frequently for-profit forms of clinical experimentation with stem cells. In doing so, I trace the institutionalization of experimental clinical stem cell research and applications in China, its stepwise problematization, and metamorphosis into an object of regulatory concern and intervention. It will become clear that the transition toward adoption of an internationally recognized standard system in the clinical stem cell field is a complex and highly contested process. The long-standing absence of a coherent statecentered regulatory approach for clinical stem cell research and applications in China, has not only given rise to the realization of new economic opportunities, but also to a multi-stranded innovation culture, which is characterized by knowledge exchanges and collaborations between highly diverging socio-technical and epistemic communities. I will make sense of these processes through the concept of "national experimental pluralism".
Introduction
Clinical research for new drugs and medical technologies in China has in recent years been marked by the striving toward independent innovation and the strengthening of domestic research, testing and production infrastructures (Ding et al., 2011) . This trend has been accompanied by the adoption of international scientific and ethical clinical research standards, promulgated in regulations for the administration of clinical trials, their ethical review, and mandatory certification of research hospitals according to Good Clinical Practice (GCP) guidelines (CURE, 2009; Li, 2011) .
International standards also manifest in closer adherence to evidence-based medicine (EBM) protocols for the evaluation of new medicines, observed by the Chinese State Food and Drug Administration (SFDA), especially since its reform in 2007 (Li et al, 2008) . The propagation of international standard regimens initially focused particularly on the development of conventional drug products, but was extended more recently to evaluation procedures in Traditional Chinese Medicine (Tang et al, 2008) , for gene therapies (Peng et al, 2008) , and other advanced medical technologies (Qiu, 2009 ).
In contrast, clinical stem cell research and applications, focused on in this article, have only lately become the object of regulatory attention in China. A first attempt, within the context of a regulation for novel medical technologies, was introduced in 2009 (Cyranoski, 2009 ). However, this attempt was never completed and a new and more comprehensive regulatory approach has been in preparation since 2008. The Chinese Ministry of Health (MOH) has issued a first phase of this evolving regulatory framework in January 2012 (MOH, 2012) . Harmonization with the international system, however, has with this initial step not yet been realized.
In this article, I delineate the institutionalization of experimental clinical stem cell research and applications in China since the early 2000s. I show a stepwise problematization of the field of stem cell research and its metamorphosis into an object of regulatory concern and intervention. In part one, I provide an overview of the diverging modalities of stem cell-based clinical experimentation in China, and introduce the actor groups that push for the adoption of internationally recognized research standards and regulatory protocols. In part two, I focus on the problematization and emerging regulatory situation of the clinical stem cell field in China. Then, in part three, I show that the long-lasting absence of a coherent statecentered regulatory approach for clinical stem cell research and applications in China, has given rise to a multi-stranded innovation culture, which is characterized by knowledge exchanges and collaborations between highly diverging socio-technical and epistemic communities. I analyze these processes through the concepts of "national experimental pluralism".
The article is based on eight months fieldwork in China and Hong Kong conducted between July 2009 and April 2011. Eighty-two interviews were carried out with stem cell researchers, staff of biotech companies, bioethicists, policy makers and patients. The article draws, furthermore, on observations of scientific conferences, expert meetings, visits to hospitals and research centers, and on documentary research, that included the analysis of policy documents, scientific journals, newspapers, websites and television programs.
Experimental stem cell research and applications in China
Experimental interventions using stem, or stem cell-like, cells have been carried out in China for more than ten years (Song, 2010) . Enabled by the long-standing absence of state regulation for this new research field, a broad range of experimental approaches using stem cells has emerged during this period. These interventions range from cases of obvious fraud (BBC, 2009 ), through to highly formalized SFDAapproved clinical trials. The overwhelming bulk of experimental implantations of stem cells in China, however, fall in between these two poles. They are carried out as
(1) patient-driven experimental treatments, (2) profit-driven experimental therapies, and (3) research-driven observational or clinical pilot studies. A fourth group is comprised of the highly systematized phases I and II (soon III) clinical trials that have intermittently been approved by the SFDA since 2004 (Liao and Zhao, 2008) . While the forms of clinical experimentation with stem cells in China do often diverge from international standard regimens, a slow but steady move toward the adoption of internationally recognized clinical research protocols is evident in recent years.
Significantly, this transition process has not primarily been propelled by the state, but by the agency of a select group of Chinese high-profile researchers and their international research partners. These groups have worked continuously to transform and standardize local research infrastructures and to harmonize conceptions of clinical research methodology and ethics with international standards. These efforts have taken place through capacity building and scientific self-governance efforts in the context of concrete clinical projects and beyond the level of state agency (Rosemann, 2012) . The MOH, the government unit responsible for clinical stem cell research, has for many years been hesitant in its approach to the governance of clinical SC research and applications in China.
1 The MOH has, however, facilitated the adoption of 1 Note: While basic stem cell research falls under the joint responsibility of the Ministries of Health and Science and Technology (see Salter and Qiu,2009) , clinical research and applications falls solely under the responsibility of the MOH.
international standards in the stem cell field indirectly, by promoting EBM in medical education (Li et al, 2008) , by imposing stringent regulations for drug evaluation procedures by the SFDA, and by demanding GCP certification for research hospitals (Li, 2011) . Furthermore, as will be shown in part two, the MOH is currently in the process of issuing a comprehensive regulatory approach for clinical stem cell research and applications. This step will undoubtedly propel and formalize the transition toward the adoption of international standards further. Before commenting on these issues in greater detail, however, I provide a brief overview of the four central modalities of experimental clinical intervention with stem cells that can be observed in China today: patient-driven, profit-driven and science-driven forms of clinical experimentation. with some having been reported in medical journals (Gu et al, 2003; Zhu, 2006) and shown repeatedly on state television (see for example, CCTV, 2007 CCTV, , 2010 . Such patient-driven forms of experimental treatments are commonly provided by doctors in first-tier hospitals, and are not usually linked to commercial interests. As the head of a clinical research institute in a large hospital in Beijing pointed out, fees may be charged, but these are restricted to operating expenses for hospital beds, material and equipment. Costs for patients or their families do not involve the salary for hospitals or doctors. Experimental treatments are commonly provided to patients of a clinical specialist, who tests a newly developed treatment approach, on a small number of his or her most seriously ill patients. Sometimes, particularly if conducted in first-tier hospitals, the results of these clinical experiments are recorded and presented at medical conferences, and occasionally published in peer-reviewed medical journals (Peng et al., 2005; Li et al, 2007) .
Patient-versus profit-driven experimental interventions with stem cells
Profit-driven experimental therapies, on the other hand, follow a different pattern. (Qiu, 2009; Song, 2011 Furthermore, the shift is facilitated because patients expect to pay for experimental treatments in the strongly commercialized health-care system of China. This has been pointed out in interviews with both, clinicians and patients. Consequently, some of these clinical service providers make substantial amounts of money. Beike Company, for instance, which has treated more than 9000 patients, has reportedly generated one hundred million US dollars until 2010 alone (Sipp, 2012 ). An estimate in the journal Nature states that there were between 100-150 for-profit stem cell clinics in China in
2009, but the actual number is uncertain (Cyranoski, 2009 ).
Research-driven experimentations with stem cells
A broad range of research-driven clinical stem cell applications is going on in China. (Wang, 2009 ). These conditions, and the apparent success of the experimental treatment in a first patient, justified more interventions and, prior to September 2010, more than 130 experimental treatment episodes had been provided (Chen, 2010) . As reported by the PI of this study at a stem cell conference in China in 2010, systematic records of the treatment results were taken of all patients along some standardized outcome measures (ibid.). A colleague of this researcher commented, however, that the design and results of such observational treatment series are far from systematic enough to be accepted by a good journal. In his view, though, these data provide important precursory information on the efficacy and safety of specific treatment pathways, which then can be tested in systematic clinical trials later.
In addition to such semi-systematized observational studies, however, a larger number of more systematically designed clinical studies have been carried out in
China. These studies qualify either as clinical pilot studies or as randomized clinical trials, of which only very few involve control groups (see for example Wang et al, 2007) . Liao and Zhao, in a review of 18 publications of clinical stem cell research in China, concluded in 2008 that, even though important progress in the field has been made, some of the trials were not done well. In certain hospitals, for instance, cells were used that were not well characterized (2008, p. 613) . They argue that without mandatory SFDA approval of stem cell clinical trials, data on the safety and efficacy of these studies cannot be guaranteed (ibid.).
The Move toward International Integration
What can be observed in the clinical stem cell field in China today is a slow but steady move toward the adoption of internationally recognized standard protocols.
Two parties in particular propel this transition. The first is a small group of highprofile researchers in China who aim to develop SFDA-approved stem cell-based medicinal products, which can be formally marketed in China, and reported in top Until January 2012, however, clinical trials with stem cell-based medical technologies had to be subject exclusively to hospital intern IRB review. While this situation has amplified possibilities for clinical experimentations, it has simultaneously deprived several researchers of the chance to obtain approval and feedback by a national-level drug regulatory authority. According to the founder of a stem cell R&D company in Northern China, this has in many institutes prevented a boost in research quality, and has increased safety risks for partaking patients. (Rosemann, 2012) . As members of the network emphasized in interviews, these criteria must be met, to satisfy the requirements of the drug regulatory authorities from the four regions, as well as to create compliance with publication criteria of top international journals. experiences which emerge at the interface of technology research, politics and culture (Ong, 2010, p.13) . Articulations of ethics can evolve at different levels and scales (that is, patients, professional groups, states, companies, religious collectivities, etcetera), and reflect tensions between the priorities and worldviews of specific stakeholders or social groups. They are, furthermore, closely bound to issues of power and representation (Sleeboom-Faulkner, 2010) . Regulation, in contrast, refers here to the efforts of states to shape the governance of technology research in relation to public interests (Van Zwanenberg et al, 2011, p. 12) .
In regulatory debates on clinical stem cell research in China, a tension can be observed between forms of ethical reasoning that prioritize the stringent protection of human experimental subjects, and opinions that emphasize the value of rapid scientific progress for economic and social development. In the latter register, we see a climate of high expectations and hope that has been initiated by the media, scientists, clinical service providers, as well as politicized innovation and development discourse. The first experimental treatments with stem-or stem cell-like cells in the early 2000s, for example, were by the media celebrated as important breakthrough advancements (Liu and Xing, 2002; CCTV, 2002) , and as indicators of China's rapid scientific progress (CCTV, 2003) . Supportive coverage on experimental stem cell therapies on China's state television has continued over the years, with treatment episodes framed as indicators of scientific development and hope for patients (CCTV, 2003 (CCTV, , 2007 (CCTV, , 2010 . Positive associations with experimental for-profit stem cell therapies in China have been reinforced furthermore, through high profile advertising campaigns launched by stem cell clinics, who use photos of high-ranked politicians posing with clinical service providers, and a political discourse that highlights rapid and independent innovation and technology-driven economic development (Song, 2011; Sipp, 2012) . Risks for patients and doubts regarding the efficacy of experimental stem cell therapies are commonly downplayed in such representations.
Notwithstanding these campaigns, the safety, feasibility and profit-driven (Huang, 2007) . Calls for systematized forms of evidencing were also demanded by the influential news magazine Southern Weekend, which asked whether an initially highly praised experimental treatment for SCI is a "science bubble" rather than a "striking breakthrough". The article concludes with a plea for more controlled randomized clinical trials in China (Southern Weekend, 2006) . Furthermore, calls for reliable regulation have come from high-profile, Chinese researchers (Liao and Zhao, 2008) , as well from scientists and commentators from abroad (Cyranoski, 2009 (Cyranoski, , 2012 ISSCR, 2008; Hyun, 2010) .
The MOH, which is the government unit responsible for the regulation of clinical research and applications in China, has reacted to these demands in three signaled that stringent controls for experimental stem cell therapies were unlikely to be carried out in the near future. In the light of a growing demand for these therapies, these providers decided upon investment and market expansion.
The emergence of a comprehensive regulation
In 2008 the Science and Education unit of the MOH authorized an expert committee of medical ethics chaired by Prof Chingli Hu, to develop a comprehensive draft regulation for clinical research and applications with human stem cell in China. After a two-year consultation and preparation process, a draft was submitted to the MOH in October 2010. This proposal has subsequently been under internal consideration, and is expected to form the foundation of a finalized version that is expected soon.
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A central premise of this draft is the promotion of standardized and rigorous scientific forms of clinical stem cell research (Hu et al, 2010, p.27 Group', co-founded by the MOH and SFDA in Beijing (paragraph 2). The task of these province-level workgroups is to appraise the incoming data, to produce summarizing reports to Beijing (paragraph 4), and during later stages, to play an active role in the implementation and enforcement of the regulation (paragraph 2).
Self-correction means that all institutes that have not yet received approval, either by the MOH or the SFDA, must stop clinical stem cell research or application activities until approval has been obtained. Institutes that continue to carry out unauthorized clinical research or applications have been announced to be targeted as focal points for rectification (paragraph 2). On the other hand, clinical trials for stem cell products that have obtained approval by the SFDA are expected to act in strict accordance with the requirements set out by the SFDA, and in compliance with the Chinese GCP standards (paragraph 2). The document has announced that no registration applications will be accepted by the MOH or the SFDA until July 1 2012 (paragraph 2). Information on how applications for registration will be handled, however, has not been provided in the text. Uncertainty also remains as to how noncompliance will be dealt with, and which role the MOH and its province-level workgroups will play in this. It is not clear, furthermore, whether military hospitals (that operate under the command of the Health Department of the Army General Logistics Department), will be subjected to the same review and approval procedures as state hospitals, or whether a different regulatory approach shall apply.
National experimental pluralism
With the January 2012 notification, and the draft regulation of 2010, the ministry has signaled that it is committed to methodical preclinical studies, approval procedures based on systematic clinical trials, controls of cell processing and manufacturing, and to the penalization and shutting down of clinics that do not meet required standards. laboratories (Gong et al, 2012) . Most important maybe, the large number of clinical applications with MSC has given rise to crucial hands-on experiences, in particular regarding cell transplantation and related surgical procedures, and to the availability of a clinical infrastructure, which can be used for systematic and multi-center clinical trials in the future.
Conclusions
In this article I have tracked the stepwise transformation of experimental clinical stem cell research and applications in China to an object of regulatory concern and intervention. It has become clear, that initial steps toward regulatory harmonization have been undertaken, but that more specific regulatory instruments will be required, should not be too stringent, so as not to inhibit scientific progress and delay public health and economic benefits.
Against this background, internal pressures for conformity with the international system can be expected to remain low. However, external forms of pressure for regulatory harmonization in the clinical stem cell field are currently also not very strong. In contrast to pharmaceutical drug research, in which international harmonization has been enforced by drug regulatory agencies and the pharmaceutical industry, the pressure is still low in regenerative stem cell medicine. A key reason for this, I suggest, is that the regenerative medicine field is still at an early development stage. Until now, the therapeutic potential of stem cell-based therapies has only in few cases been demonstrated convincingly. Cross-border marketing of stem cell based products or procedures are still low, and it is mainly restricted to the informal sector.
Investments from the pharmaceutical industry, moreover, have remained small. In the light of this situation, and the concrete forms of exchange and use value that the stemcell-mode-of-production in China is already generating, the broad spectrum of experimental scientific and ethical practices to which this article has referred to, is well likely to persist.
